メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
藤田医科大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
医学部・救急医学・総合内科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(8)
研究成果
(40)
フィンガープリント
医学部・救急医学・総合内科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Cyclic Derivative
60%
GABA Derivatives
60%
Isolated Perfused Rat Heart
55%
Etomoxir
50%
Heart Function
50%
Amnesia
50%
Procedural Sedation
50%
Procedural Analgesia
50%
Post-occlusive Reactive Hyperemia
50%
Muscarinic Receptors
50%
SARS-CoV-2 Pneumonia
50%
Ceramide
50%
Amiodarone
50%
Intralipid
50%
Diacylglycerol
50%
Simultaneous Quantitation
50%
Flame Ionization Detection
50%
Ischemic Preconditioning
50%
GABAA Receptor (GABAAR)
50%
Cycloheximide
50%
Severe Bradycardia
50%
Sofosbuvir
50%
Ca2+ Pump
50%
Mechanical Signals
50%
Endoscopic Screening
50%
Favipiravir
50%
SARS-CoV-2 Infection
50%
Refractory Septic Shock
50%
Retrospective Longitudinal Study
50%
7-day Mortality
50%
Overview of Reviews
50%
Review Protocol
50%
Vaccination
50%
Screening Decisions
50%
Umbrella Review
50%
Decision Aid
50%
Injection Site Reaction
50%
Japan
50%
MRNA-1273
50%
Obesity Phenotypes
50%
Metabolically Abnormal Obesity
50%
Mask Ventilation
50%
Reactive Hyperemia
42%
Radiographic Testing
41%
Screening Effect
37%
Metabolically Healthy
36%
Time to Defervescence
30%
Metabolically Healthy Obese
27%
Bradycardia
25%
Cardiac Contractility
25%
Plasma Membrane H+-ATPase
25%
Attendance Rate
25%
Intention to Screen
25%
Self-selection Bias
25%
Old Japanese
25%
First Dose
25%
Second Dose
25%
Metabolically Abnormal Obese
22%
Diabetic Rat Heart
22%
BK Channel
21%
Anti-amnesic Effect
20%
Muscarinic ACh Receptor
20%
Late Treatment
20%
Reperfusion
16%
Ribavirin
16%
Ischemia
16%
Chronic Hepatitis C
16%
2,3-dihydroxybenzoic Acid
16%
Salicylic Acid
16%
Cell Remodeling
16%
Opportunistic Screening
16%
Fatty Acid Composition
16%
Presentation Format
16%
AOPCP
14%
No-flow
14%
Cancer Outcomes
12%
Coronary Flow
12%
Orthovanadate
12%
Cardioinhibitory
12%
Propensity Scoring
12%
Critical Care
12%
Do-not-resuscitate Orders
12%
Emergency Intensive Care Unit
12%
Bias Correction
12%
East Asian Studies
12%
Per-protocol Effect
12%
Data Assessment
12%
Diabetic Cardiomyopathy
11%
Non-ischemic
11%
Protein Kinase
11%
Neuronal Network
10%
Receptor-binding Domain
10%
Protein Synthesis
10%
Step-down
10%
Retention Test
10%
Scopolamine
10%
Passive Avoidance
10%
Aniracetam
10%
Latency
10%
GABA Antagonist
10%
Medicine and Dentistry
Emergency Department
100%
Adverse Event
100%
Cross Sectional Study
66%
Intubation
65%
Tracheal Intubation
60%
Observational Study
57%
Airway Obstruction
50%
Infection
50%
Streptococcus Pneumoniae
50%
Procedural Sedation and Analgesia
50%
Nefiracetam
50%
Choline Acetyltransferase
50%
Sofosbuvir
50%
Intralipid
50%
Severe Acute Respiratory Syndrome Coronavirus 2
50%
Muscarinic Acetylcholine Receptor
50%
Pulmonary Pathology
50%
Amiodarone
50%
Mixed Infection
50%
Snakebite
50%
COVID-19
50%
Cohort Analysis
50%
Injection Site Reaction
50%
Reverse Transcription Loop Mediated Isothermal Amplification
50%
Septic Shock
50%
Noradrenalin
50%
Favipiravir
50%
Retrospective Study
50%
Umbrella Review
50%
Magnetic Resonance Imaging
50%
Prevalence
50%
Mask Ventilation
50%
Body Mass Index
33%
Odds Ratio
32%
Logistic Regression Analysis
25%
Pathogen
25%
Respiratory Failure
25%
Pneumococcal Infection
25%
Diffuse Alveolar Damage
25%
Histopathology
25%
Bronchopneumonia
25%
Recurrent Disease
25%
Intensive Care Unit
21%
Ribavirin
16%
Chronic Hepatitis C
16%
Atherosclerosis
16%
Antihypertensive Agent
16%
Cardiovascular Risk
16%
Carotid Atherosclerosis
16%
Risk Stratification
16%
Brain Ischemia
16%
Fibrous Cap
16%
Morphology
16%
Hazard Ratio
14%
Physiological Stress
12%
Mass Radiography
12%
Heart Arrest
10%
Acetamide
10%
Gamma-Aminobutyric Acid
10%
RNA Directed RNA Polymerase
10%
Airway Management
8%
Prostate Hypertrophy
8%
Drug Interaction
8%
Antivirus Agent
8%
Faintness
8%
Chronic Atrial Fibrillation
8%
Hypoxemia
7%
Intensive Care
7%
Breast Cancer Screening
6%
Health Technology
5%
Technology Assessment
5%
Nasopharyngeal Swab
5%
Injury
5%
Overdiagnosis
5%
Upper Gastrointestinal Series
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diacylglycerol
100%
Cycloheximide
100%
Fatty Acid
66%
4 Aminobutyric Acid
60%
Adverse Event
50%
Etomoxir
50%
Takotsubo Cardiomyopathy
50%
Hyperaemia
50%
Choline Acetyltransferase
50%
Amiodarone
50%
Muscarinic Receptor
50%
Intralipid
50%
Snakebite
50%
Ceramide
50%
Nefiracetam
50%
Sofosbuvir
50%
Cohort Study
50%
Intubation
50%
Favipiravir
50%
Malignant Neoplasm
50%
Ischemia
33%
Protein Kinase C
21%
Acetamide
20%
Ribavirin
16%
2,3 Dihydroxybenzoic Acid
16%
Chronic Hepatitis C
16%
Randomized Controlled Trial
15%
Dyskinesia
12%
Snake Venom
12%
Receptor
10%
GABA Receptor Antagonist
10%
Glucose
10%
Binding Site
10%
Picrotoxin
10%
Bicuculline
10%
Aniracetam
10%
Scopolamine
10%
Receptor Antagonist
10%
Hypoxemia
10%
RNA Directed RNA Polymerase
10%
Colorectal Carcinoma
10%
Breast Cancer
10%
Prostate Cancer
10%
Prostate Hypertrophy
8%
Acylglycerol
8%
Chlorobutanol
8%
Faintness
8%
Antivirus Agent
8%
Chronic Atrial Fibrillation
8%
Drug Interaction
8%
Diabetic Cardiomyopathy
7%
Uridine Triphosphate
7%
Orthovanadic Acid
7%
Sodium Thiopental
7%
4-Aminopyridine
6%
5' Nucleotidase
6%
Heart Arrest
5%
Heart Arrhythmia
5%
Hypotension
5%
Pandemic
5%
Lung Cancer
5%